Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

To determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD). The ACCORD Lipid Trial wa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2014-03, Vol.37 (3), p.686-693
Hauptverfasser:	LINZ, Peter E, LOVATO, Laura C, PAPADEMETRIOU, Vasilios, GINSBERG, Henry N, ELAM, Marshall B, BYINGTON, Robert P, O'CONNOR, Patrick J, LEITER, Lawrence A, WEISS, Daniel, FORCE, Rex W, CROUSE, John R, ISMAIL-BEIGI, Faramarz, SIMMONS, Debra L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Analysis Biological and medical sciences Blood Glucose Cardiovascular disease Cholesterol Cholesterol, HDL Cholesterol, HDL - drug effects Clinical Care/Education/Nutrition/Psychosocial Research Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Diabetic Angiopathies - drug therapy Double-Blind Method Drug therapy Drug Therapy, Combination - methods Dyslipidemias - drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Fenofibrate Fenofibrate - therapeutic use Humans Hypoglycemic Agents - therapeutic use Hypolipidemic Agents - therapeutic use Lipid Metabolism - drug effects Lipids Male Measurement Medical sciences Medical treatment Metabolic diseases Middle Aged Patient outcomes Risk assessment Risk Factors Simvastatin - therapeutic use Thiazolidinediones - therapeutic use Treatment Outcome Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!